{"pmid":32438333,"title":"COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis.","text":["COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis.","OBJECTIVE: The objective of this study was to evaluate the pooled estimate of diabetes prevalence in young (<50 years) versus elderly (>50 years) COVID-19 cohorts. METHODS: Studies published between December-2019 and March-2020 reporting demographic and clinical characteristics of COVID-19 cases were identified. A total of 11 studies included accounting for 2084 COVID-19 patients. RESULTS: The overall prevalence of diabetes in COVID-19 patients with a mean age>50 years was 13.2%, whereas studies with relatively younger patients (mean age <50 years) had a pooled prevalence of 9.0% CONCLUSION: The overall prevalence of diabetes in COVID-19 patients was found to be 13.2% with studies including relatively elderly patients showing higher rates of diabetes. The intermingled effects of diabetes with other cardiovascular comorbidities warrant age-specific outcomes data including the impact of ongoing antidiabetic treatment.","Diabetes Metab Syndr","Desai, Rupak","Singh, Sandeep","Parekh, Tarang","Sachdeva, Sonali","Sachdeva, Rajesh","Kumar, Gautam","32438333"],"abstract":["OBJECTIVE: The objective of this study was to evaluate the pooled estimate of diabetes prevalence in young (<50 years) versus elderly (>50 years) COVID-19 cohorts. METHODS: Studies published between December-2019 and March-2020 reporting demographic and clinical characteristics of COVID-19 cases were identified. A total of 11 studies included accounting for 2084 COVID-19 patients. RESULTS: The overall prevalence of diabetes in COVID-19 patients with a mean age>50 years was 13.2%, whereas studies with relatively younger patients (mean age <50 years) had a pooled prevalence of 9.0% CONCLUSION: The overall prevalence of diabetes in COVID-19 patients was found to be 13.2% with studies including relatively elderly patients showing higher rates of diabetes. The intermingled effects of diabetes with other cardiovascular comorbidities warrant age-specific outcomes data including the impact of ongoing antidiabetic treatment."],"journal":"Diabetes Metab Syndr","authors":["Desai, Rupak","Singh, Sandeep","Parekh, Tarang","Sachdeva, Sonali","Sachdeva, Rajesh","Kumar, Gautam"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438333","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.dsx.2020.05.021","keywords":["antidiabetic treatment","covid-19","diabetes mellitus","elderly","prevalence","type-2 diabetes"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667521393717149696,"score":9.490897,"similar":[{"pmid":32407746,"pmcid":"PMC7214308","title":"Prevalence of diabetes mellitus in 2019 novel coronavirus: a Meta-analysis.","text":["Prevalence of diabetes mellitus in 2019 novel coronavirus: a Meta-analysis.","BACKGROUND: Since December 2019, a new strain ofcoronavirus named 2019 novel coronavirus (2019-nCoV) has been discovered in Wuhan. The prevalence of diabetes mellitus, which is a great public health issue leading to immunity inhibition and anincreased incidenceofinfections, has been increasing over the past ten years. The aim of this research was to systematically assess the prevalence of diabetes mellitus among 2019-nCoV. METHODS: We searched PubMed, Embase, Web of Science and Medline for observational studies up to February 25, 2020. A random effects model or fixed-effects model was applied to evaluate the pooled prevalence of diabetes mellitus and odds ratio (OR) with 95% confidence interval (CI). FINDINGS: In total, nine papers met the eligibility criteria. The pooled prevalence of DM was 9% (95% CI 6%-12%). There was obvious heterogeneity (I(2) 65%, p=0.004) in the prevalence of DM in these studies. The prevalence of DM in moderate patients with 2019-nCoV was 7% (95% CI 4%-10%). The prevalence of DM in severe patients with 2019-nCoV was 17% (95% CI 13%-21%). The prevalence of DM in severe patients with 2019-nCoV was significantly higher than that in moderate patients with 2019-nCoV (OR 2.49, 95% CI 1.70 to 3.64). INTERPRETATION: To our knowledge, this work is the first report showing the prevalence of diabetes mellitus in patients with 2019-nCoV, which is beneficial to prevent the spread of 2019-nCoV in the future.","Diabetes Res Clin Pract","Wang, Xiang","Wang, Shoujun","Sun, Liangge","Qin, Guijun","32407746"],"abstract":["BACKGROUND: Since December 2019, a new strain ofcoronavirus named 2019 novel coronavirus (2019-nCoV) has been discovered in Wuhan. The prevalence of diabetes mellitus, which is a great public health issue leading to immunity inhibition and anincreased incidenceofinfections, has been increasing over the past ten years. The aim of this research was to systematically assess the prevalence of diabetes mellitus among 2019-nCoV. METHODS: We searched PubMed, Embase, Web of Science and Medline for observational studies up to February 25, 2020. A random effects model or fixed-effects model was applied to evaluate the pooled prevalence of diabetes mellitus and odds ratio (OR) with 95% confidence interval (CI). FINDINGS: In total, nine papers met the eligibility criteria. The pooled prevalence of DM was 9% (95% CI 6%-12%). There was obvious heterogeneity (I(2) 65%, p=0.004) in the prevalence of DM in these studies. The prevalence of DM in moderate patients with 2019-nCoV was 7% (95% CI 4%-10%). The prevalence of DM in severe patients with 2019-nCoV was 17% (95% CI 13%-21%). The prevalence of DM in severe patients with 2019-nCoV was significantly higher than that in moderate patients with 2019-nCoV (OR 2.49, 95% CI 1.70 to 3.64). INTERPRETATION: To our knowledge, this work is the first report showing the prevalence of diabetes mellitus in patients with 2019-nCoV, which is beneficial to prevent the spread of 2019-nCoV in the future."],"journal":"Diabetes Res Clin Pract","authors":["Wang, Xiang","Wang, Shoujun","Sun, Liangge","Qin, Guijun"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407746","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabres.2020.108200","keywords":["2019 novel coronavirus","diabetes mellitus","meta-analysis","prevalence"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666950579806535681,"score":333.70618},{"pmid":32408118,"title":"Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.","text":["Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.","BACKGROUND: Many studies on COVID-19 have reported diabetes to be associated with severe disease and mortality, however, the data is conflicting. The objectives of this meta-analysis were to explore the relationship between diabetes and COVID-19 mortality and severity, and to determine the prevalence of diabetes in patients with COVID-19. METHODS: We searched the PubMed for case-control studies in English, published between Jan 1 and Apr 22, 2020, that had data on diabetes in patients with COVID-19. The frequency of diabetes was compared between patients with and without the composite endpoint of mortality or severity. Random effects model was used with odds ratio as the effect size. We also determined the pooled prevalence of diabetes in patients with COVID-19. Heterogeneity and publication bias were taken care by meta-regression, sub-group analyses, and trim and fill methods. RESULTS: We included 33 studies (16,003 patients) and found diabetes to be significantly associated with mortality of COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1.37-2.64; p < 0.01). Diabetes was also associated with severe COVID-19 with a pooled odds ratio of 2.75 (95% CI: 2.09-3.62; p < 0.01). The combined corrected pooled odds ratio of mortality or severity was 2.16 (95% CI: 1.74-2.68; p < 0.01). The pooled prevalence of diabetes in patients with COVID-19 was 9.8% (95% CI: 8.7%-10.9%) (after adjusting for heterogeneity). CONCLUSIONS: Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. Further studies on the pathogenic mechanisms and therapeutic implications need to be done.","Diabetes Metab Syndr","Kumar, Ashish","Arora, Anil","Sharma, Praveen","Anikhindi, Shrihari Anil","Bansal, Naresh","Singla, Vikas","Khare, Shivam","Srivastava, Abhishyant","32408118"],"abstract":["BACKGROUND: Many studies on COVID-19 have reported diabetes to be associated with severe disease and mortality, however, the data is conflicting. The objectives of this meta-analysis were to explore the relationship between diabetes and COVID-19 mortality and severity, and to determine the prevalence of diabetes in patients with COVID-19. METHODS: We searched the PubMed for case-control studies in English, published between Jan 1 and Apr 22, 2020, that had data on diabetes in patients with COVID-19. The frequency of diabetes was compared between patients with and without the composite endpoint of mortality or severity. Random effects model was used with odds ratio as the effect size. We also determined the pooled prevalence of diabetes in patients with COVID-19. Heterogeneity and publication bias were taken care by meta-regression, sub-group analyses, and trim and fill methods. RESULTS: We included 33 studies (16,003 patients) and found diabetes to be significantly associated with mortality of COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1.37-2.64; p < 0.01). Diabetes was also associated with severe COVID-19 with a pooled odds ratio of 2.75 (95% CI: 2.09-3.62; p < 0.01). The combined corrected pooled odds ratio of mortality or severity was 2.16 (95% CI: 1.74-2.68; p < 0.01). The pooled prevalence of diabetes in patients with COVID-19 was 9.8% (95% CI: 8.7%-10.9%) (after adjusting for heterogeneity). CONCLUSIONS: Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. Further studies on the pathogenic mechanisms and therapeutic implications need to be done."],"journal":"Diabetes Metab Syndr","authors":["Kumar, Ashish","Arora, Anil","Sharma, Praveen","Anikhindi, Shrihari Anil","Bansal, Naresh","Singla, Vikas","Khare, Shivam","Srivastava, Abhishyant"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408118","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.dsx.2020.04.044","keywords":["2019-ncov","covid-19","coronavirus","diabetes mellitus","novel coronavirus","sars-cov-2","ncov-2019"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666802845404364800,"score":296.85696},{"pmid":32315817,"pmcid":"PMC7195434","title":"Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis.","text":["Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis.","BACKGROUND: Since being first reported in Wuhan, China, in December 8, 2019, the outbreak of the novel coronavirus, now known as COVID-19, has spread globally. Some case studies regarding the characteristics and outcome of patients with COVID-19 have been published recently. We conducted a meta-analysis to evaluate the risk factors of COVID-19. METHODS: Medline, SinoMed, EMBASE, and Cochrane Library were searched for clinical and epidemiological studies on confirmed cases of COVID-19. RESULTS: The incidence of fever, cough, fatigue, and dyspnea symptoms were 85.6 % (95CI 81.3-89.9 %), 65.7 % (95CI 60.1-71.4 %), 42.4 % (95CI 32.2-52.6 %) and 21.4 % (95CI 15.3-27.5 %). The prevalence of diabetes was 7.7 % (95CI 6.1-9.3 %), hypertension was 15.6 % (95CI 12.6-18.6 %), cardiovascular disease was 4.7 % (95CI 3.1-6.2 %), and malignancy was 1.2 % (95CI 0.5-1.8 %). The complications, including ARDS risk, ranged from 5.6-13.2 %, with the pooled estimate of ARDS risk at 9.4 %, ACI at 5.8 % (95CI 0.7-10.8 %), AKI at 2.1 % (95CI 0.6-3.7 %), and shock at 4.7 % (95CI 0.9-8.6 %). The risks of severity and mortality ranged from 12.6 to 23.5% and from 2.0 to 4.4 %, with pooled estimates at 18.0 and 3.2 %, respectively. The percentage of critical cases in diabetes and hypertension was 44.5 % (95CI 27.0-61.9 %) and 41.7 % (95CI 26.4-56.9 %), respectively. CONCLUSION: Fever is the most common symptom in patients with COVID-19. The most prevalent comorbidities are hypertension and diabetes which are associated with the severity of COVID-19. ARDS and ACI may be the main obstacles for patients to treatment recovery. The case severe rate and mortality is lower than that of SARS and MERS.","J Clin Virol","Hu, Yong","Sun, Jiazhong","Dai, Zhe","Deng, Haohua","Li, Xin","Huang, Qi","Wu, Yuwen","Sun, Li","Xu, Yancheng","32315817"],"abstract":["BACKGROUND: Since being first reported in Wuhan, China, in December 8, 2019, the outbreak of the novel coronavirus, now known as COVID-19, has spread globally. Some case studies regarding the characteristics and outcome of patients with COVID-19 have been published recently. We conducted a meta-analysis to evaluate the risk factors of COVID-19. METHODS: Medline, SinoMed, EMBASE, and Cochrane Library were searched for clinical and epidemiological studies on confirmed cases of COVID-19. RESULTS: The incidence of fever, cough, fatigue, and dyspnea symptoms were 85.6 % (95CI 81.3-89.9 %), 65.7 % (95CI 60.1-71.4 %), 42.4 % (95CI 32.2-52.6 %) and 21.4 % (95CI 15.3-27.5 %). The prevalence of diabetes was 7.7 % (95CI 6.1-9.3 %), hypertension was 15.6 % (95CI 12.6-18.6 %), cardiovascular disease was 4.7 % (95CI 3.1-6.2 %), and malignancy was 1.2 % (95CI 0.5-1.8 %). The complications, including ARDS risk, ranged from 5.6-13.2 %, with the pooled estimate of ARDS risk at 9.4 %, ACI at 5.8 % (95CI 0.7-10.8 %), AKI at 2.1 % (95CI 0.6-3.7 %), and shock at 4.7 % (95CI 0.9-8.6 %). The risks of severity and mortality ranged from 12.6 to 23.5% and from 2.0 to 4.4 %, with pooled estimates at 18.0 and 3.2 %, respectively. The percentage of critical cases in diabetes and hypertension was 44.5 % (95CI 27.0-61.9 %) and 41.7 % (95CI 26.4-56.9 %), respectively. CONCLUSION: Fever is the most common symptom in patients with COVID-19. The most prevalent comorbidities are hypertension and diabetes which are associated with the severity of COVID-19. ARDS and ACI may be the main obstacles for patients to treatment recovery. The case severe rate and mortality is lower than that of SARS and MERS."],"journal":"J Clin Virol","authors":["Hu, Yong","Sun, Jiazhong","Dai, Zhe","Deng, Haohua","Li, Xin","Huang, Qi","Wu, Yuwen","Sun, Li","Xu, Yancheng"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315817","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jcv.2020.104371","keywords":["covid-19","comorbidities","mortality","severity","symptom"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138493460414465,"score":252.98892},{"pmid":32496012,"title":"Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection.","text":["Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection.","AIMS: Diabetes mellitus is one of the most common comorbidities in Coronavirus disease 2019 (COVID-19) patients. The objective of this study was to evaluate the influences of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection. MATERIALS AND METHODS: Medical records of 66 hospitalized COVID-19 patients were collected and classified into non-severe (mild/moderate cases) and severe (severe/critical cases) groups, respectively. Logistic regression analysis was used to estimate the risk of severe COVID-19 (severe/critical infection). In addition, a meta-analysis including published studies reported the impacts of diabetes mellitus on severity and fatality of COVID-19, and our current study was conducted using fixed-effects models. RESULTS: There were 22 diabetic and 44 non-diabetic cases among the 66 hospitalized COVID-19 patients. As the results shown, seven cases (31.82%) were diagnosed as severe COVID-19 in diabetic patients, which was significantly higher than that in non-diabetic group (4/44, 9.09%, P = 0.033). After adjustment for age and gender, the results showed that diabetes mellitus was significantly associated with COVID-19 severity (OR: 5.29, 95% CI: 1.07-26.02). A meta-analysis further confirmed the positive association between diabetes mellitus and COVID-19 severity (pooled OR = 2.58, 95% CI: 1.93-3.45). Moreover, the diabetic patients infected with SARS-CoV-2 showed to have 2.95-fold higher risk of fatality compared to those patients without diabetes mellitus (95% CI: 1.93-4.53). CONCLUSIONS: Our findings provide new evidences that diabetes mellitus is associated with a higher risk of severity and fatality of COVID-19. Therefore, intensive monitoring and antidiabetic therapy should be considered in diabetic patients with SARS-CoV-2 infection. This article is protected by copyright. All rights reserved.","Diabetes Obes Metab","Wu, Jing","Zhang, Jingqi","Sun, Xiaohua","Wang, Lijuan","Xu, Yunfang","Zhang, Yuanyuan","Liu, Xingxiang","Dong, Chen","32496012"],"abstract":["AIMS: Diabetes mellitus is one of the most common comorbidities in Coronavirus disease 2019 (COVID-19) patients. The objective of this study was to evaluate the influences of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection. MATERIALS AND METHODS: Medical records of 66 hospitalized COVID-19 patients were collected and classified into non-severe (mild/moderate cases) and severe (severe/critical cases) groups, respectively. Logistic regression analysis was used to estimate the risk of severe COVID-19 (severe/critical infection). In addition, a meta-analysis including published studies reported the impacts of diabetes mellitus on severity and fatality of COVID-19, and our current study was conducted using fixed-effects models. RESULTS: There were 22 diabetic and 44 non-diabetic cases among the 66 hospitalized COVID-19 patients. As the results shown, seven cases (31.82%) were diagnosed as severe COVID-19 in diabetic patients, which was significantly higher than that in non-diabetic group (4/44, 9.09%, P = 0.033). After adjustment for age and gender, the results showed that diabetes mellitus was significantly associated with COVID-19 severity (OR: 5.29, 95% CI: 1.07-26.02). A meta-analysis further confirmed the positive association between diabetes mellitus and COVID-19 severity (pooled OR = 2.58, 95% CI: 1.93-3.45). Moreover, the diabetic patients infected with SARS-CoV-2 showed to have 2.95-fold higher risk of fatality compared to those patients without diabetes mellitus (95% CI: 1.93-4.53). CONCLUSIONS: Our findings provide new evidences that diabetes mellitus is associated with a higher risk of severity and fatality of COVID-19. Therefore, intensive monitoring and antidiabetic therapy should be considered in diabetic patients with SARS-CoV-2 infection. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Obes Metab","authors":["Wu, Jing","Zhang, Jingqi","Sun, Xiaohua","Wang, Lijuan","Xu, Yunfang","Zhang, Yuanyuan","Liu, Xingxiang","Dong, Chen"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32496012","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/dom.14105","keywords":["covid-19","diabetes","fatality","severity"],"topics":["Treatment"],"weight":1,"_version_":1668712823861018624,"score":241.975},{"pmid":32305882,"pmcid":"PMC7195018","title":"Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.","text":["Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.","BACKGROUND: The prognostic significance of diabetes mellitus (DM) in patients with coronavirus 2019 disease (COVID-19) remains unknown. OBJECTIVES: To assess the risk of ICU admission and morality risk in diabetic COVID-19 patients. STUDY DESING: A database search was conducted to identify studies comparing diabetic COVID-19 patients hospitalized in intensive care unit (ICU) and those reporting the overall mortality of these patients published up to March 25, 2020 within MEDLINE, Scopus and Web of Science. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in abstracting data and assessing validity. Quality assessment was performed using the Newcastle-Ottawa quality assessment scale. The main outcome was the risk of ICU admission in diabetic patients with COVID-19 infection while the second was the mortality risk in overall diabetic COVID-19 patients. Data were pooled using the Mantel-Haenszel random effects models with odds ratio (OR) as the effect measure with the related 95 % confidence interval (CI). Statistical heterogeneity between groups was measured using the Higgins I(2) statistic. RESULTS: Among 1382 patients (mean age 51.5 years, 798 males), DM resulted to be the second more frequent comorbidities. Diabetic patients resulted to have a significant increased risk of ICU admission (OR: 2.79, 95 % CI 1.85-4.22, p < 0.0001, I(2) = 46 %). In 471 patients (mean age 56.6 years, 294 males) analysed for the secondary outcome diabetic subjects resulted to be at higher mortality risk (OR 3.21, 95 % CI 1.82-5.64, p < 0.0001, I(2) = 16 %). CONCLUSIONS: Diabetic patients with COVID-19 patients are at higher risk of ICU admission and show an higher mortality risk.","J Clin Virol","Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","Zuliani, Giovanni","32305882"],"abstract":["BACKGROUND: The prognostic significance of diabetes mellitus (DM) in patients with coronavirus 2019 disease (COVID-19) remains unknown. OBJECTIVES: To assess the risk of ICU admission and morality risk in diabetic COVID-19 patients. STUDY DESING: A database search was conducted to identify studies comparing diabetic COVID-19 patients hospitalized in intensive care unit (ICU) and those reporting the overall mortality of these patients published up to March 25, 2020 within MEDLINE, Scopus and Web of Science. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in abstracting data and assessing validity. Quality assessment was performed using the Newcastle-Ottawa quality assessment scale. The main outcome was the risk of ICU admission in diabetic patients with COVID-19 infection while the second was the mortality risk in overall diabetic COVID-19 patients. Data were pooled using the Mantel-Haenszel random effects models with odds ratio (OR) as the effect measure with the related 95 % confidence interval (CI). Statistical heterogeneity between groups was measured using the Higgins I(2) statistic. RESULTS: Among 1382 patients (mean age 51.5 years, 798 males), DM resulted to be the second more frequent comorbidities. Diabetic patients resulted to have a significant increased risk of ICU admission (OR: 2.79, 95 % CI 1.85-4.22, p < 0.0001, I(2) = 46 %). In 471 patients (mean age 56.6 years, 294 males) analysed for the secondary outcome diabetic subjects resulted to be at higher mortality risk (OR 3.21, 95 % CI 1.82-5.64, p < 0.0001, I(2) = 16 %). CONCLUSIONS: Diabetic patients with COVID-19 patients are at higher risk of ICU admission and show an higher mortality risk."],"journal":"J Clin Virol","authors":["Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","Zuliani, Giovanni"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305882","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jcv.2020.104354","keywords":["covid-19","diabetes","icum","ortality"],"topics":["Treatment"],"weight":1,"_version_":1666138493405888512,"score":236.21832}]}